With oncology pipeline at ‘inflection point,’ Merck puts finish line in focus with new corporate campaign
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- MRK Merck+1.9% 18d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Merck belongs to, so it often moves with news about it.
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+7.8% 30d
AbbVie is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+6.9% 30d
Abbott Laboratories is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- PFE Pfizer+5.5% 30d
Pfizer is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MRK | -2.47% | +3.37% | base | +3.94% | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | +3.08% | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | +0.62% | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | +3.82% | after close | after close | after close |
| ABBV | +0.13% | +3.12% | base | +2.66% | after close | after close | after close |
| ABT | -6.15% | -2.89% | base | +5.93% | after close | after close | after close |
| PFE | -1.67% | +1.73% | base | +2.70% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
With oncology pipeline at ‘inflection point,’ Merck puts finish line in focus with new corporate campaign Fierce Pharma
Source: Fierce Pharma
Energy
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | +2.66% | final price |
| ABBV | three days earlier | +3.12% | final price |
| ABBV | five days earlier | +0.13% | final price |
| ABT | that day | +5.93% | final price |
| ABT | three days earlier | -2.89% | final price |
| ABT | five days earlier | -6.15% | final price |
| JNJ | that day | +3.82% | final price |
| JNJ | three days earlier | +2.66% | final price |
| JNJ | five days earlier | +1.93% | final price |
| LLY | that day | +0.62% | final price |
| LLY | three days earlier | +0.54% | final price |
| LLY | five days earlier | -8.42% | final price |
| MRK | that day | +3.94% | final price |
| MRK | three days earlier | +3.37% | final price |
| MRK | five days earlier | -2.47% | final price |
| PFE | that day | +2.70% | final price |
| PFE | three days earlier | +1.73% | final price |
| PFE | five days earlier | -1.67% | final price |
| XLV | that day | +3.08% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 51 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 33 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 47 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid the energy case looks
12 out of 100
“With oncology pipeline at ‘inflection point,’ Merck puts finish line in focus with new corporate campaign” scores 12 out of 100. The score uses 1 sources.